Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q7131441> ?p ?o }
Showing triples 1 to 61 of
61
with 100 triples per page.
- Q7131441 subject Q7427150.
- Q7131441 subject Q8431759.
- Q7131441 subject Q8515266.
- Q7131441 subject Q8546974.
- Q7131441 abstract "Panobinostat (LBH-589, trade name Farydak) is a drug developed by Novartis for the treatment of various cancers. It is a hydroxamic acid and acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor).On 23 February 2015 it received FDA accelerated approval for use in patients with multiple myeloma who had received at least 2 previous treatments, including bortezomib and an immunomodulatory agent." after clinical trials.".
- Q7131441 atcPrefix "L01".
- Q7131441 atcSuffix "XX42".
- Q7131441 bioavailability "21.0".
- Q7131441 casNumber "404950-80-7".
- Q7131441 chEBI "85990".
- Q7131441 fdaUniiCode "9647FM7Y3Z".
- Q7131441 iupacName "(2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide".
- Q7131441 pubchem "6918837".
- Q7131441 thumbnail Panobinostat_structure.svg?width=300.
- Q7131441 wikiPageWikiLink Q1088072.
- Q7131441 wikiPageWikiLink Q1130172.
- Q7131441 wikiPageWikiLink Q1142055.
- Q7131441 wikiPageWikiLink Q128581.
- Q7131441 wikiPageWikiLink Q1365309.
- Q7131441 wikiPageWikiLink Q14599311.
- Q7131441 wikiPageWikiLink Q14864427.
- Q7131441 wikiPageWikiLink Q14916187.
- Q7131441 wikiPageWikiLink Q17145978.
- Q7131441 wikiPageWikiLink Q174378.
- Q7131441 wikiPageWikiLink Q181257.
- Q7131441 wikiPageWikiLink Q209369.
- Q7131441 wikiPageWikiLink Q221681.
- Q7131441 wikiPageWikiLink Q30612.
- Q7131441 wikiPageWikiLink Q32089.
- Q7131441 wikiPageWikiLink Q3569101.
- Q7131441 wikiPageWikiLink Q419319.
- Q7131441 wikiPageWikiLink Q420327.
- Q7131441 wikiPageWikiLink Q467635.
- Q7131441 wikiPageWikiLink Q5014970.
- Q7131441 wikiPageWikiLink Q507154.
- Q7131441 wikiPageWikiLink Q5196687.
- Q7131441 wikiPageWikiLink Q5512671.
- Q7131441 wikiPageWikiLink Q580290.
- Q7131441 wikiPageWikiLink Q7427150.
- Q7131441 wikiPageWikiLink Q7647199.
- Q7131441 wikiPageWikiLink Q7843332.
- Q7131441 wikiPageWikiLink Q8431759.
- Q7131441 wikiPageWikiLink Q8515266.
- Q7131441 wikiPageWikiLink Q8546974.
- Q7131441 wikiPageWikiLink Q954625.
- Q7131441 atcPrefix "L01".
- Q7131441 atcSuffix "XX42".
- Q7131441 bioavailability "21.0".
- Q7131441 casNumber "404950".
- Q7131441 chebi "85990".
- Q7131441 iupacName "-N-hydroxy-3-[4-phenyl]acrylamide".
- Q7131441 pubchem "6918837".
- Q7131441 unii "9647".
- Q7131441 type ChemicalSubstance.
- Q7131441 type Drug.
- Q7131441 type ChemicalObject.
- Q7131441 type Thing.
- Q7131441 type Q8386.
- Q7131441 comment "Panobinostat (LBH-589, trade name Farydak) is a drug developed by Novartis for the treatment of various cancers. It is a hydroxamic acid and acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor).On 23 February 2015 it received FDA accelerated approval for use in patients with multiple myeloma who had received at least 2 previous treatments, including bortezomib and an immunomodulatory agent." after clinical trials.".
- Q7131441 label "Panobinostat".
- Q7131441 depiction Panobinostat_structure.svg.